title: Use of recombinant human soluble thrombomodulin in the management of HELLP syndrome complicated by DIC.
authors.forename: T
authors.initials: T
authors.lastname: Ikezoe
authors.forename: N
authors.initials: N
authors.lastname: Ikenoue
authors.forename: N
authors.initials: N
authors.lastname: Uchikawa
authors.forename: S
authors.initials: S
authors.lastname: Kojima
authors.forename: T
authors.initials: T
authors.lastname: Fukaya
authors.forename: A
authors.initials: A
authors.lastname: Yokoyama
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D001777:Blood Coagulation / Q000187:drug effects*; D002585:Cesarean Section; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D017359:HELLP Syndrome / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D011247:Pregnancy; D011994:Recombinant Proteins / Q000008:administration & dosage; D018180:Thrombomodulin / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D011994:Recombinant Proteins; C546931:THBD protein, human; D018180:Thrombomodulin